Skip to contentClarengateINTELLIGENCE
Companies/SC651132

Tay Therapeutics Limited

Research and experimental development on biotechnology · Dundee

ActiveUnited KingdomIncorporated 2020Private Limited Company
Register Ask analyst

Documents & history

Available account evidence and business events. This is not a complete filing history or document library.

Accounts to 2026-01-31

IXBRL · 117 source facts · 24 selected values

Not assessed
legacy record
Reporting period
2025-02-01 to 2026-01-31
Extraction status
Legacy / not assessed
Numeric facts
72
Documents processed
Not recorded
XBRL standards validation
Not assessed
Filing-profile validation
Not assessed
Parser
Legacy parser
Taxonomy
FRS-102-2025-01-01.xsd
Currency
GBP
Source identifier
Prod223_4257_SC651132_20260131
Source archive
Accounts_Bulk_Data-2026-07-07.zip

Accounts to 2026-01-31

IXBRL · 117 source facts · 24 selected values

Validation findings
XBRL valid
Reporting period
2025-02-01 to 2026-01-31
Extraction status
complete
Numeric facts
72
Documents processed
1
XBRL standards validation
valid
Filing-profile validation
invalid
Parser
arelle 2.44.4
Taxonomy
FRS-102-2025-01-01.xsd
Currency
GBP
Source identifier
Prod224_2607_SC651132_20260131
Source archive
Accounts_Monthly_Data-July2026.zip

Extraction findings: filing rules invalid. These describe source processing, not an audit opinion on the company.

Accounts to 2025-01-31

IXBRL · 88 source facts · 21 selected values

Validation findings
XBRL valid
Reporting period
2024-02-01 to 2025-01-31
Extraction status
complete
Numeric facts
42
Documents processed
1
XBRL standards validation
valid
Filing-profile validation
invalid
Parser
arelle 2.44.4
Taxonomy
FRS-102-2023-01-01.xsd
Currency
GBP
Source identifier
Prod224_2506_SC651132_20250131
Source archive
Accounts_Monthly_Data-June2025.zip

Extraction findings: filing rules invalid. These describe source processing, not an audit opinion on the company.

Accounts to 2024-01-31

IXBRL · 88 source facts · 21 selected values

Not assessed
legacy record
Reporting period
2023-02-01 to 2024-01-31
Extraction status
Legacy / not assessed
Numeric facts
42
Documents processed
Not recorded
XBRL standards validation
Not assessed
Filing-profile validation
Not assessed
Parser
Legacy parser
Taxonomy
FRS-102-2023-01-01.xsd
Currency
GBP
Source identifier
Prod224_2266_SC651132_20240131
Source archive
Accounts_Monthly_Data-June2024.zip

Accounts to 2023-01-31

IXBRL · 89 source facts · 21 selected values

Not assessed
legacy record
Reporting period
2022-02-01 to 2023-01-31
Extraction status
Legacy / not assessed
Numeric facts
42
Documents processed
Not recorded
XBRL standards validation
Not assessed
Filing-profile validation
Not assessed
Parser
Legacy parser
Taxonomy
FRS-102-2021-01-01.xsd
Currency
GBP
Source identifier
Prod224_0021_SC651132_20230131
Source archive
Accounts_Monthly_Data-July2023.zip

Accounts to 2022-01-31

IXBRL · 90 source facts · 30 selected values

Not assessed
legacy record
Reporting period
2021-02-01 to 2022-01-31
Extraction status
Legacy / not assessed
Numeric facts
59
Documents processed
Not recorded
XBRL standards validation
Not assessed
Filing-profile validation
Not assessed
Parser
Legacy parser
Taxonomy
FRS-102-2019-01-01.xsd
Currency
GBP
Source identifier
Prod224_0107_SC651132_20220131
Source archive
Accounts_Monthly_Data-June2022.zip

Accounts to 2021-01-31

IXBRL · 32 source facts · 10 selected values

Not assessed
legacy record
Reporting period
2020-01-10 to 2021-01-31
Extraction status
Legacy / not assessed
Numeric facts
13
Documents processed
Not recorded
XBRL standards validation
Not assessed
Filing-profile validation
Not assessed
Parser
Legacy parser
Taxonomy
FRS-102-2019-01-01.xsd
Currency
GBP
Source identifier
Prod224_0094_SC651132_20210131
Source archive
Accounts_Monthly_Data-September2021.zip

Registered details

SC651132
Status
Active
Type
Private Limited Company
Incorporated
2020-01-10
Jurisdiction
—
Registered office
LIFE SCIENCES INNOVATION HUB, 5 JAMES LINDSAY PLACE, DUNDEE, DD1 5JJ, SCOTLAND

Classification

1 SIC codes
72110

Capital & company events

Reconstructed equity rounds and matched research funding.

Equity fundraising

0 SH01-derived rounds

No reconstructed allotment rounds.

Research and innovation

2 matched grants
Exploiting read-through compounds as novel anticancer agents with a unique mechanism of actionLead
Innovate UK · Collaborative R&D · 2023-10-01 – 2025-09-30
£349,786
awarded
Discovery of a first in class oral anti-inflammatory drug for eczemaLead
Innovate UK · Collaborative R&D · 2021-05-01 – 2022-02-28
£77,279
awarded